Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors-Reference-Cited by-同舟云学术

Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

Published:2021-10-20 Issue:616 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Cazanave Sophie C.¹^ORCID,Warren Andrew D.¹^ORCID,Pacula Maciej¹,Touti Fayçal¹,Zagorska Anna²,Gural Nil³,Huang Eric K.¹^ORCID,Sherman Sarah,Cheema Mehar¹,Ibarra Sabrina¹^ORCID,Bates Jamie²^ORCID,Billin Andrew N.²,Liles John T.²,Budas Grant R.²,Breckenridge David G.²^ORCID,Tiniakos Dina⁴⁵^ORCID,Ratziu Vlad⁶,Daly Ann K.⁴⁵^ORCID,Govaere Olivier⁴⁵^ORCID,Anstee Quentin M.⁴⁵^ORCID,Gelrud Louis⁷,Luther Jay⁸,Chung Raymond T.⁹^ORCID,Corey Kathleen E.⁸,Winckler Wendy¹,Bhatia Sangeeta³^ORCID,Kwong Gabriel A.¹⁹^ORCID

Affiliation:

1. Glympse Bio Inc., Cambridge, MA 02138, USA.

2. Gilead Sciences Inc., Foster City, CA 94404, USA.

3. Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

4. Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.

5. Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 7RU, UK.

6. Sorbonne Université, ICAN (Institute of Cardiometabolism And Nutrition), Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne University, INSERM UMRS 1138 CRC, Paris 75013, France.

7. Bon Secours St Mary’s Hospital, Richmond VA 23226, USA.

8. Liver Center, GI Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

9. The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA 30332, USA.

Abstract

A urinary test for liver protease activity detects NASH fibrosis and indicates early therapeutic treatment response.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference64 articles.

1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

2. From NASH to HCC: current concepts and future challenges

3. Non-biopsy methods to determine hepatic fibrosis;Fierbinteanu-Braticevici C.;J. Med. Life,2009

4. Liver biopsy: The best, not the gold standard

5. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhalable point-of-care urinary diagnostic platform;Science Advances;2024-01-05

2. FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1;Hepatology;2023-10-24

3. Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH);Science Translational Medicine;2023-10-04

4. Inhalable point-of-care urinary diagnostic platform;2023-10-02

5. Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non‐alcoholic fatty liver disease, steatohepatitis, and fibrosis;The FASEB Journal;2023-02-21